KMT2A and acute myeloid leukemia: Finally, CRISPR/Cas9-mediated genome editing has been used to create a model of Kmt2a-Mllt3 AML via dual single-guide RNAs simultaneous targeting the breakpoint cluster region of Kmt2a and Mllt3 (70).